Clinical Trials on Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Italy

Total 127 results

Fondazione IRCCS Istituto Nazionale dei Tumori,...
European Institute of Oncology; ASST Santi Paolo e Carlo

Recruiting

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment (APPROACH)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Italy
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer (PERSIAN)

Oligometastatic Hormone Sensitive Prostate Cancer

Italy
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

Korea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Nerviano Medical Sciences

Completed

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer

Italy
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Metastatic Castration-sensitive Prostate Cancer

United States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
National Cancer Institute, Naples

Active, not recruiting

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Metastatic Castration-resistent Prostate Cancer

Italy
Azienda Ospedaliero-Universitaria Careggi

Completed

Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer (ANCHISES)

Metastatic Prostate Cancer | Elderly Patients

Italy
Fondazione del Piemonte per l'Oncologia
National Cancer Institute (NCI); University of Pisa; Royal Marsden NHS Foundation... and other collaborators

Recruiting

An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum

Prostate Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Prostate Cancer Aggressiveness

Italy
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Prostate Cancer | Cancer of the Prostate | Hormone Sensitive Prostate Cancer

Canada, United States, France, Spain, Australia, Sweden, Taiwan, Finland, Korea, Republic of, Netherlands, United Kingdom, Denmark, Brazil, Slovakia, Austria, Italy, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer

United States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
National Cancer Institute, Naples

Completed

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer (ZANTE)

Metastatic Prostate Cancer

Italy
University Ghent
University Hospital, Geneva

Active, not recruiting

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Metastatic | Oligometastatic Cancer

Norway, Spain, Belgium, Switzerland, Australia, Italy
Azienda Unità Sanitaria Locale Reggio Emilia

Recruiting

Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study) (ReCaP)

Rehabilitation | Metastatic Prostate Cancer (PCa) in ADT

Italy
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (WB-LuPSMA)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Italy
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. (IRSTB030)

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer | Circulating Tumor Cells

Italy
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) (LU-PSMA)

Metastatic Castration Resistant Prostate Cancer | 68Ga-PSMA PET/CT Positive

Italy
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Ipsen

Terminated

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer

France, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Sanofi

Completed

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Prostate Cancer Metastatic

United Kingdom, Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain
AB Science

Completed

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer

Italy, Russian Federation, India, Canada, France, Malaysia
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
CureVac

Completed

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

Hormonal Refractory Prostate Cancer

Germany, Italy
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
Istituto Scientifico Romagnolo per lo Studio e...
Bayer

Recruiting

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (RAPSON)

Metastatic Castration-resistant Prostate Cancer

Italy
Hinova Pharmaceuticals USA, Inc.

Active, not recruiting

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Germany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
SOTIO a.s.

Completed

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)

Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
Bayer

Active, not recruiting

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Bone Metastatic Castration-resistant Prostate Cancer

France, Lithuania, Israel, Italy, United Kingdom, Austria
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
Astellas Pharma Europe Ltd.
Medivation, Inc.

Completed

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (PREMISE)

Metastatic Castration Resistant Prostate Cancer

Czechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
IRCCS San Raffaele

Recruiting

Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

Prostate Cancer

Italy
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
Bayer

Completed

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)

Bone Metastases | Hormone Refractory Prostate Cancer

Italy, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
European Organisation for Research and Treatment...

Completed

Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases

Prostate Cancer | Metastatic Cancer

Netherlands, Denmark, Belgium, Poland, Switzerland, United Kingdom, Italy, Russian Federation, Portugal
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
AstraZeneca
Merck Sharp & Dohme LLC

Completed

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer

Belgium, France, Italy, Netherlands, Poland, United States, Canada, Czechia, Russian Federation, United Kingdom, Spain
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients (BonEnza)

Prostate Cancer | Bone Metastases

Italy
UNICANCER
Sanofi; European Organisation for Research and Treatment of Cancer - EORTC; I... and other collaborators

Active, not recruiting

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer (PEACE1)

Metastatic Prostate Cancer

France, Ireland, Spain, Switzerland, Belgium, Italy, Romania
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
IRCCS San Raffaele

Recruiting

Liver Embolization Approaches for Tumor Management (LEATUM)

Hepatocellular Carcinoma | Metastatic Cancer | Primary Liver Cancer | Cholangiocarcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer | Metastatic Colon Cancer

Italy
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, Germany, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway, Czechia, Finland, Hong Kong, Netherlands, Poland, Spain, Sweden, Turkey, Denmark, Hungary, Italy, United Kingdom, ... and more
Agennix

Completed

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Prostate Cancer | Hormone Refractory Prostate Cancer

United States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Hoffmann-La Roche

Active, not recruiting

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Janssen Research & Development, LLC

Completed

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Metastatic Prostate Cancer

United States, Korea, Republic of, Australia, Poland, Taiwan, France, Thailand, Malaysia, Russian Federation, Canada, Bulgaria, Italy, Spain, Turkey, Sweden, Israel, Belarus, Ukraine, Brazil, Argentina, Belgium, Denmark, United Kingdom and more
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia

Clinical Trials on Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations